SEC Form 10-K filed by SELLAS Life Sciences Group Inc.
$SLS
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/21/2021 | $18.00 | Overweight | Cantor Fitzgerald |
4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
Cantor Fitzgerald initiated coverage of SELLAS Life Sciences with a rating of Overweight and set a new price target of $18.00
RBC Capital initiated coverage of Solaris Resources with a rating of Outperform and set a new price target of $18.00
4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
10-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
– Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events – – First Patient Dosed in Phase 2 Trial of SLS009 in Newly Diagnosed First Line AML – – Reported Positive Phase 2 Data of SLS009 in Relapsed/Refractory (r/r) AML at ASH 2025 – – $71.8 Million in Cash and Cash Equivalents as of December 31, 2025; Additional $42.6 Million in Proceeds Received in Q1 2026 to Date Through Warrant Exercises – NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of nov
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that preclinical data on SLS009 (tambiciclib), a potent, selective CDK9 inhibitor, will be presented in a poster session at the American Association for Cancer Research (AACR) taking place April 17-22 at San Diego Convention Center in San Diego, CA. The abstracts will be published in the online Proceedings of the AACR. Exposure of acute myeloid leukemia (AML) cell lines to increasing concentrations of SLS009 for 6 hours r
- Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS' Predictive Biomarker and AI Assisted Precision Medicine Models to be Utilized -- Topline Data Expected in Q4 2026 – NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the first patient has been enrolled in its randomized Phase 2 trial evaluating SLS009 (tambiciclib), a highly selective CDK9 inhibitor in newly diagnosed, first-line acute myeloid leuk
Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the addition of Linghua Wang, MD, PhD, to its Scientific Advisory Board (SAB). Dr. Wang is a widely respected leader in cancer research and translational science, and she joins the Company's SAB shortly after the appointments of Philip C. Amrein, MD, and Dr. Alex Kentsis, MD, PhD. "We are thrilled to welcome Dr. Wang to our Scientific Advisory Board," said Dragan Cicic, MD, Senior Vice President, Chief Development Officer
Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biot
NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reminds the investment community that it will host a virtual investor symposium on its lead asset, galinpepimut-S (GPS), including the potential commercial opportunity for GPS in AML patients. The conference call and webcast will be held on Thursday, September 15, 2022, from 1:00 p.m. to 2:00 p.m. ET featuring remarks from Angelos Stergiou, M.D., Sc.D. h.c., President and Chief Executive Officer, and Robert Francomano, Chief Commer
NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today reported its financial results for the quarter ended September 30, 2021 and provided a business update. "During the third quarter of 2021, in addition to continuing to enroll patients in the United States and Europe for our Phase 3 REGAL study of galinpepimut-S (GPS) in acute myeloid leukemia (AML) patients, we also commenced clinical and regulatory preparations for a potential new Phase 2/3 study of GPS in AML patients following a bon
Reported Promising Updated Clinical Data in Ongoing Clinical Trials of Galinpepimut-S (GPS) in Combination with PD-1 Inhibitors for Malignant Pleural Mesothelioma (MPM) and WT1+ Advanced Ovarian Cancer Recently Published Outcomes Data for Acute Myeloid Leukemia (AML) Patients Highlights Continued Unmet Need and Expanded Market Opportunity for GPS Cash Position of $29.9 million as of June 30, 2021 To Host Virtual Investor Symposium on GPS on August 17, 2021 NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad ran
SC 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)
SC 13G - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)
SC 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)